SavePeptides
SavePeptidesCompound
Re-checked hourly
All peptides
Weight LossFDA-approvedVendors pending
FDA-approvedVendors pendingFacts verified · 2026-05-25

Mazdutide

Also known as ibi-362, ly-3305677, oxm-3 · Wikipedia

Mazdutide (IBI-362 / LY-3305677 / OXM-3) is a once-weekly dual GLP-1 and glucagon receptor agonist based on the native oxyntomodulin scaffold with lipid acylation for extended half-life. It was developed by Eli Lilly and out-licensed to Innovent Biologics for the China market. Mazdutide received NMPA approval in China for chronic weight management (June 2025) and type 2 diabetes (September 2025) on the strength of the Phase III GLORY program. It is not FDA- or EMA-approved. Mazdutide is also under evaluation for MASH and hypertension indications.

—

best

price

—

per

mg

—

vendors

tracked

FDA-approved

stage

Vendor data

Coming soon.

Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.

Browse all vendors

Mechanism of action

Mazdutide is an acylated oxyntomodulin-like dual agonist at the GLP-1 and glucagon receptors. GLP-1 receptor activation produces appetite suppression, slowed gastric emptying, and glucose-dependent insulin secretion.

Mazdutide is an acylated oxyntomodulin-like dual agonist at the GLP-1 and glucagon receptors. GLP-1 receptor activation produces appetite suppression, slowed gastric emptying, and glucose-dependent insulin secretion. Glucagon receptor activation drives hepatic lipolysis, increased energy expenditure, and reduced hepatic steatosis — features distinguishing dual agonism from pure GLP-1 mimetics. Fatty-acid acylation enables albumin binding for a ~6-8 day plasma half-life and weekly subcutaneous dosing. Phase 2 and Phase 3 data in Chinese adults with obesity and type 2 diabetes have shown dose-dependent weight loss and HbA1c reduction (Ji et al., PMID 38092790).

Pharmacokinetic properties

Half-life

~6-8 days subcutaneous

Routes

subcutaneous

Bioavailability

Lipidated peptide for once-weekly dosing; not orally bioavailable.

Amino-acid sequence

(Oxyntomodulin analog; long peptide with acylation; see NCATS entry)

Use & research dosing

Appetite ControlWeight Loss

Approved in China for chronic weight management at 4 mg or 6 mg subcutaneous weekly and for type 2 diabetes at 4 mg weekly, with titration over approximately 16 weeks from a 1.5 mg starting dose. Phase 2 evaluated up to 6 mg weekly; Phase 1b explored up to 10 mg weekly with acceptable tolerability. Not FDA- or EMA-approved. Research framing only for use outside China.

Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.

Editorial perspective

Current state: Mazdutide is the first dual GLP-1/glucagon agonist to receive a regulatory approval anywhere (China NMPA, 2025), giving it a stronger evidence base than most incretin candidates in this category outside the US. Weight loss in Chinese populations at 6 mg appears competitive with tirzepatide. FDA registration has not been pursued. Compounded mazdutide outside China carries the usual research-chemical caveats around purity and labeling accuracy.

— SavePeptides editorial desk · last updated 2026-05-25

Cautions & contraindications

Before researching this compound, note:

  • Personal or family history of medullary thyroid carcinoma or MEN2
  • History of pancreatitis
  • Pregnancy and breastfeeding
  • GI side effects (nausea, vomiting, diarrhea) common during titration
  • Potential modest increases in heart rate and blood pressure
  • Glucagon component may modestly elevate fasting glucose at higher doses — monitor in T2D
  • Possible increase in hepatic glucose output — caution in advanced liver disease
  • Not FDA-approved; compounded vendor product quality varies

Research foundation

The papers behind the page.

  1. [01]https://pubmed.ncbi.nlm.nih.gov/38092790/
  2. [02]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561728/

Facts verified

2026-05-25

Confidence

medium

What this means

  • NMPA-approved in China only — not FDA or EMA
  • Most Phase III data are from Chinese populations
  • Long-term cardiovascular outcome data limited

How we check →

Vendor data coming soon

All vendors

001 — Independent

We don't list what we wouldn't research.

SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.

002 — Vendor-funded

Free to browse. Supported by referrals.

SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.

003 — Research use

Research-use disclaimer.

SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.